TELTOW, BERLIN, GERMANY / ACCESSWIRE / July 12, 2017 / Today, CO.DON AG received the Commission’s implementing decision of 10.07.2017 on the granting of marketing authorization for the human pharmaceutical product,
We are using cookies to give you the best experience on our site. Cookies are files stored in your browser and are used by most websites to help personalise your web experience. By continuing to use our website without changing the settings, you are agreeing to our use of cookies.
x
TELTOW, BERLIN, GERMANY / ACCESSWIRE / July 12, 2017 / Today, CO.DON AG received the Commission’s implementing decision of 10.07.2017 on the granting of marketing authorization for the human pharmaceutical product,
European Union (EU) regulators yesterday recommended approval of a third-generation transplant product of autologous cultured cartilage cells for repairing worn-out knees that doesn’t require any scaffold material.
KFAR SABA, Israel, Dec. 20, 2016 /PRNewswire/ — CartiHeal (2009) Ltd., developer of a cell-free, off-the-shelf implant for use in cartilage and osteochondral defects, announced today the FDA approval of the Investigational Device Exemption (IDE) application submitted by CartiHeal for their Agili-C™ implant, towards a PMA application.
Sobi has come to an agreement with TiGenix for the early termination of their existing commercial relationships and will return the distribution rights for ChondroCelect to TiGenix.
CENTENNIAL, Colo., Jan. 19, 2016 /PRNewswire-USNewswire/ — AlloSource®, one of the nation’s largest providers of cartilage, cellular, bone, skin and soft-tissue allografts for use in surgical procedures and wound care to advance patient healing, was awarded U.S. Patent Number 9,186,253, titled Cartilage mosaic compositions and methods, for its new cartilage repair allograft, ProChondrix® Cartilage Restoration Matrix.
AlloSource recently joined the ICRS as a corporate member as well as a silver sponsor for the upcoming ICRS world congress Sorrento.
Press Release: Piramal Enterprises announces sale of its Canada-based cartilage repair product, BST-CarGel® to Smith & Nephew Montreal, January 12, 2016: Piramal Enterprises Limited (‘PEL’, NSE: PEL, BSE: 500302) today announces the sale of BST-CarGel® from Piramal Healthcare (Canada) Limited, based in Montreal, Canada to Smith & Nephew (NYSE:SNN;LSE:SN), the global medical technology business. BST-CarGel® is a first-line cartilage repair product used along with microfracture and other bone marrow stimulation techniques for the initial treatment of most sizes of focal cartilage tears. Through this transaction, an affiliate of Smith & Nephew plc will acquire ownership of all product and intellectual property assets related to BST-CarGel.